Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation.
Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation.
复制标题
DOI：
10.1002/jcp.22999
复制
发表时间：
2012-06
影响因子：
5.6
通讯作者：
Ferrari, Giovanni
中科院分区：
文献类型：
--
作者：
Sainger, Rachana;Grau, Juan B.;Branchetti, Emanuela;Poggio, Paolo;Seefried, William F.;Field, Benjamin C.;Acker, Michael A.;Gorman, Robert C.;Gorman, Joseph H., III;Hargrove, Clark W., III;Bavaria, Joseph E.;Ferrari, Giovanni
Myxomatous Mitral valve prolapse (MVP) is the most common cardiac valvular abnormality in industrialized countries and a leading cause of mitral valve surgery for isolated mitral regurgitation. The key role of valvular interstitial cells (VICs) during mitral valve development and homeostasis has been recently suggested, however little is known about the molecular pathways leading to MVP. We aim to characterize Bone Morphogenetic Protein 4 (BMP4) as a cellular regulator of mitral valvular interstitial cell activation towards a pathologic synthetic phenotype and to analyze the cellular phenotypic changes and extracellular matrix (ECM) reorganization associated with the development of myxomatous mitral valve prolapse. Microarray analysis showed significant up regulation of BMP4-mediated signaling molecules in myxomatous MVP when compared to controls. Histological analysis and cellular characterization suggest that during myxomatous MVP development, healthy quiescent mitral VICs undergo a phenotypic activation via up regulation of BMP4-mediated pathway. In vitro hBMP4 treatment of isolated human mitral VICs mimics the cellular activation and ECM remodeling as seen in MVP tissues. The present study characterizes the cell biology of mitral VICs in physiological and pathological conditions and provides insights into the molecular and cellular mechanisms mediated by BMP4 during MVP. The ability to test and control the plasticity of VICs using different molecules may help in developing new diagnostic and therapeutic strategies for myxomatous MVP.
登录
查看更多内容
影响因子：
4.9
作者：
Steinert AF;Proffen B;Kunz M;Hendrich C;Ghivizzani SC;Nöth U;Rethwilm A;Eulert J;Evans CH
通讯作者：
Evans CH
影响因子：
18.2
作者：
Hinton RB;Yutzey KE
通讯作者：
Yutzey KE
DOI：
10.1016/s1357-2725(02)00100-0
发表时间：
2003-02-01
影响因子：
4
作者：
Taylor, PA;Batten, P;Yacoub, MH
通讯作者：
Yacoub, MH
影响因子：
158.5
作者：
Verma, Subodh;Mesana, Thierry G.
通讯作者：
Mesana, Thierry G.
影响因子：
10.5
作者：
Jiao, K;Kulessa, H;Hogan, BLM
通讯作者：
Hogan, BLM